During the three months ended June 30, 2019, and the period since acquisition, net income included $3.3 million and $8.2 million, respectively, related to amortization expense of acquired intangible assets.
The Company recorded an income tax expense of $7.3 million and $0.4 million, respectively, during the three and nine months ended June 30, 2019.
acquisition during fiscal year 2018.
During the nine months ended June 30, 2019, the net income included $0.2 million related to the step-up in value of the acquired inventories and $2.2 million related to amortization expense of acquired intangible assets.
The operating results of the semiconductor cryogenics business had been included in the Brooks Semiconductor Solutions Group segment before the plan of disposition.
Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.6 million, respectively, during the three months ended June 30, 2019 and 2018 and $1.1 million and $3.1 million, respectively, during the nine months ended June 30, 2019 and 2018.
Amortization expense for intangible assets was $26.2 million and $17.7 million, respectively, during the nine months ended June 30, 2019 and 2018.
GENEWIZ was acquired during the three months ended December 31, 2018 and therefore the misclassification did not impact any other historical periods.
The acquisition of Tec-Sem has expanded the Companyâ€™s contamination control solutions business within the Brooks Semiconductor Solutions Group segment.
serving scientific and business operations functions.
The revenues and net income from Tec-Sem included in the Company's consolidated results for the nine months ended June 30, 2019 were $27.1 million and $7.0 million, respectively.
Reserves for excess and obsolete inventory were $16.2 million and $15.0 million, respectively, at June 30, 2019 and September 30, 2018.The $1.9 million decrease during the nine months ended June 30, 2019 as compared to the corresponding period of fiscal 2018 was primarily attributable to lower foreign currency exchange losses.
The increase of $2.2 million during the third quarter of fiscal year 2019 as compared to the corresponding period of fiscal year 2018 reflects higher expense of $1.2 million within the Brooks Life Sciences segment and $1.0 million within the Brooks Semiconductor Solutions Group segment.
The syndication to a new group of lenders during the second quarter of fiscal 2019 met the criteria of a debt extinguishment and therefore the amortization of the deferred financing costs associated with the origination of the incremental term loan was accelerated and recorded as a loss on extinguishment of debt in our statement of operations.
We reported gross margins of 41.0% for the three months ended June 30, 2019 compared to 38.8% for the corresponding period of the prior fiscal year.
We reported gross margins of 40.6% for the nine months ended June 30, 2019 compared to 38.9% for the corresponding period of the prior fiscal year.
The difference in reported gross margin due to the adoption of the new revenue recognition standard was a net decrease in gross profit of $0.6 million and $1.8 million during three and nine months ended June 30, 2019, respectively.